ReViVox® is a safe, low dose, formulation of pyridostigmine under development as a reversal agent for off-target muscle paralysis after botulinum-Type A toxin injections. In the cosmetic application, ReViVox® will initially be developed as an injectable formulation. As a follow-on development, the drug may be formulated for topical delivery (e.g. ointment).
Development Path for ReViVox®